- Home
- SRPT
as 11-07-2025 3:56pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.9B | IPO Year: | 1997 |
| Target Price: | $35.93 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Hold | Number of Analysts: | 30 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.41 - $138.81 | Next Earning Date: | 11-03-2025 |
| Revenue: | $2,413,715,000 | Revenue Growth: | 47.15% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | -22.09% |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Simply Wall St.
a month ago
A Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price Gains
MT Newswires
a month ago
KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer
MT Newswires
a month ago
Sarepta Therapeutics Shares Up Pre-Bell Ahead of Presentation of Data on Muscle Dystrophy Studies
Insider Monkey
a month ago
Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results
Business Wire
a month ago
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
Pharmaceutical Technology
a month ago
FDA leaders are “acting political”, says ex-agency chief counsel
Business Wire
a month ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.